The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Lazcluze (lazertinib) for adults with non-small ...

Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...

Life-threatening lung cancer has taught me many valuable lessons and made my new normal so fulfilling. My life has changed ...

Your care for non-small-cell lung cancer (NSCLC) doesn’t end when you finish your medical therapy. Once you’ve gone through your course of treatment – which could involve a combination of ...

Lung cancer is the leading cause of cancer deaths among both men and women. Small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) are the two main types of lung cancer. Most lung ...

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. It arises as abnormal cells develop in or around the lungs and form tumors. Most cases of NSCLC are caused by smoking ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...

The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more ...

Lung Cancer in Non-Smokers: Clinicopathological and Survival Differences from Smokers - ...

The FDA has approved ensartinib in adult patients with anaplastic lymphoma kinase (ALK)–positive locally advanced or metastatic non–small cell lung cancer (NSCLC) naive to ALK treatment.